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Abstract We developed a system to study the function of the
ectodomain of RPTPK, a transmembrane protein-tyrosine
phosphatase, by fusing the HA-epitope tagged ectodomain of
RPTPK to the transmembrane and intracellular domain of the
epidermal growth factor receptor, EGFR, a receptor protein-
tyrosine kinase that is activated by dimerization. Although the
use of chemical crosslinkers shows that preformed HARPTPK^
EGFR dimers exist, bivalent anti-HA-tag antibody activated
HARPTPK^EGFR chimeras, suggesting this system may be
used to study regulation of dimerization. We used this system to
show that newborn calf serum may contain (a) potential ligand(s)
for RPTPK. Our results suggest that RPTPK dimerization and
thus activity may be affected by ligand binding. ß 2000 Fed-
eration of European Biochemical Societies. Published by Else-
vier Science B.V. All rights reserved.
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1. Introduction
Communication between cells in multicellular organisms is
an absolute requirement for the organism to develop nor-
mally. Propagation of many extracellular signals is mediated
by tyrosine phosphorylation through the receptor protein ty-
rosine kinases (RPTKs). The accepted model is that ligand-
induced dimerization brings the two kinase domains to close
proximity, allowing transphosphorylation of regulatory tyro-
sine residues and activation [1]. RPTK activation results in
phosphorylation of target proteins and initiation of signaling
cascades. One of the most studied and best characterized
RPTKs is the epidermal growth factor receptor (EGFR)
whose activation leads to multiple downstream events, includ-
ing MAPK activation.
The antagonists of the PTKs are the protein tyrosine phos-
phatases (PTPs) [1^3]. Intuitively, PTPs are as important for
the regulation of phosphotyrosine levels in proteins as the
PTKs. Receptor PTPs (RPTPs) are transmembrane proteins
forming a large subgroup of the PTP family. RPTPs are dis-
tinguished by their ectodomains but all have a single trans-
membrane domain and most RPTPs have two tandem PTP
domains. Interestingly, the majority of the catalytic activity is
retained in the membrane proximal PTP domain (RPTP-D1)
while the membrane distal domain (RPTP-D2) contains no or
very little activity [4,5]. RPTP-D2s are thought to regulate
RPTP-D1 either directly [6] or by modulating the dimeriza-
tion state of RPTP-D1s [7,8].
In contrast to the RPTKs, little is known about the mech-
anism of regulation of the RPTPs. To date, ligands have been
found for only a few RPTPs. RPTPW, RPTPU and RPTPN
form homophilic interactions, in that they serve as their
own ligand [9^13]. Contactin is a ligand for RPTPL/j and
surprisingly was also shown to interact in cis with RPTPK
[14,15]. The laminin^nidogen complex bound a speci¢c splice
variant of LAR [16]. Finally, pleiotrophin is a ligand of
RPTPL [17]. Interestingly, pleiotrophin is the ¢rst and, to
date, the only ligand shown to in£uence the catalytic activity
of a RPTP [17].
Functional [18^20] and structural [21] evidence suggests
that RPTPs may be negatively regulated by dimerization. Fur-
thermore, RPTPK dimers were detected in vivo using di¡erent
techniques, including chemical cross-linking [22] and £uores-
cence resonance energy transfer between RPTPK fusion pro-
teins fused to GFP mutants (L. Tertoolen, C. Blanchetot, G.
Jiang, J. Overvoorde, T. Hunter and J. den Hertog, submit-
ted). However, whether dimers are regulated (and how) re-
mains unknown.
Here, by fusing the ectodomain of RPTPK to the EGFR
transmembrane and kinase domain, we developed a system to
test the involvement of the ectodomain of RPTPK, as well as
potential ligands, in the regulation of dimerization. We show,
using an antibody recognizing the HA-tag in the ectodomain
of RPTPK, that the system is dependent on dimerization. The
presence of preformed dimers, detected using chemical cross-
linkers, suggests that the antibody-induced activation may be
mediated by changes in the topology of the ectodomain of
RPTPK that are conferred to the intracellular tyrosine kinase.
Furthermore, in a ¢rst attempt to ¢nd potential ligands of
RPTPK, we show that component(s) of newborn calf serum
(NCS), but not fetal calf serum (FCS) a¡ected the dimeriza-
tion state of the chimeric construct through the ectodomain of
RPTPK, suggesting that RPTPK dimerization may be modu-
lated by ligands that bind to the ectodomain.
2. Materials and methods
2.1. Constructs and reagents
PSG5-13-HARPTPK^EGFR was made by PCR with the ectodo-
main of HARPTPK (XhoI/SphI, aa 1^142) [23] and the transmem-
brane and intracellular domain of human EGFR (SphI/SmaI, aa
646^1212). YFP fusion proteins were made by introducing yellow
£uorescent protein (YFP) by PCR at position 702 of HARPTPK^
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EGFR or at position 200 of HARPTPK. Anti-phosphotyrosine anti-
bodies (PY20), goat anti-mouse (GAM), GAM-HRP, and goat anti-
rabbit-HRP were from Transduction Laboratories, anti-Mapk anti-
body were from SantaCruz. Rabbit anti-EGFR antibodies (281-7)
were a gift from B. De¢ze. 12CA5 was puri¢ed and concentrated to
an estimated ¢nal concentration of 1 mg/ml. A ¢nal concentration of
approximately 1 Wg/ml was used for 12CA5 stimulation. 12CA5-Fab
fragments were made from 12CA5 antibody using the Immunopure
Fab kit (Pierce). Concanavalin A was from Sigma.
2.2. Cell cultures and transfections
293 cells were routinely grown in DF medium supplemented with
7.5% FCS. Cells were transfected using the standard calcium-phos-
phate method [23]. Brie£y, 10-cm dishes were transfected with a total
of 20 Wg of DNA. The next day, the medium was refreshed, and left
another 16 h before harvesting. In the case of 12CA5 stimulation, the
cells were serum-starved overnight. For serum stimulation, the cells
were left overnight in medium containing 7.5% FCS to maintain rel-
atively high basal tyrosine phosphorylation, allowing detection of
stimulus-induced changes. Similar results were found after serum star-
vation, although low basal phosphorylation of RPTPK^EGFR made
it di⁄cult to see the e¡ect of NCS (data not shown).
2.3. Immunoprecipitation and Western blotting
Sub-con£uent transfected cells were stimulated as indicated, washed
twice with ice cold PBS, and lysed with cell lysis bu¡er CLB (50 mM
HEPES 7.4, 150 mM NaCl, 1 mM MgCl2, 10% glycerol, 1% Triton
X-100, 1 mM Vanadate and protease inhibitors [23]) for 20 min on
ice, harvested and centrifuged at 14 000Ug for 15 min to remove the
insoluble fraction. 12CA5 or anti-EGFR antibodies were added to the
supernatant for 2 h. The beads were carefully washed 4U with HNTG
bu¡er (20 mM HEPES pH 7.4, 150 mM NaCl, 0.1% Triton X-100,
10% glycerol), mixed with Laemmli sample bu¡er and loaded on a
7.5% SDS^PAGE gel. The proteins were transferred to PVDF mem-
brane using a semi-dry transfer system. After Coomassie staining, the
membrane was blocked for 1 h with 5% milk in TBST (50 mM Tris
pH 8.0, 150 mM NaCl, 0.05% Tween-20), incubated with the ¢rst
antibody for 1.5 h, washed 4U with TBS^Tween, incubated with
secondary antibody for 1 h, washed 4U with TBST, and developed
using enhanced chemiluminescence (ECL).
2.4. Crosslinking
Transfected cells were washed twice with ice cold PBS and left
30 min on ice with PBS containing 1 mg/ml of BS3 (Sigma). After
incubation, cells were carefully washed 3U with PBS and lysed in a
Tris-based CLB for 20 min on ice. After harvesting, insoluble particles
were spun down, protein concentration was measured before loading
equal amounts on gel.
3. Results and discussion
We wanted to develop a system to study the role of the
ectodomain of RPTPK and the e¡ect of potential ligands.
To this end, we made fusion proteins with the HA-tagged
ectodomain of RPTPK fused to the transmembrane and intra-
cellular domain of the human EGF receptor (EGFR),
HARPTPK^EGFR (Fig. 1A). EGFR is well known to be
activated by dimerization (Fig. 1A). Binding of EGF to the
ectodomain of EGFR, leads to the stabilization of dimers.
After ligand binding, EGFR is activated by transphosphory-
lation (Fig. 1A). Since RPTPK may be regulated by dimeriza-
tion, EGFR seemed to be a good choice to fuse to RPTPK.
3.1. Constitutive dimerization of HARPTPK^EGFR chimeras
mediated by the transmembrane domain
To test the dimeric state of the fusion protein, we used the
chemical crosslinker BS3. Since BS3 does not cross the plasma
membrane, only complexes that interact extracellularly are
detected. A band at the expected size for a dimer was detected
in cells transfected with HARPTPK^EGFR after crosslinking
(Fig. 2A), suggesting the presence of in vivo dimers. To test
which part of the protein was involved in dimerization, we
made a panel of deletion mutants. The high molecular weight
of HARPTPK^EGFR made the detection of dimer di⁄cult.
Therefore, we replaced the large intracellular domain of
HARPTPK^EGFR by YFP in order to detect the protein
and dimers more easily (Fig. 1B). Dimers were e⁄ciently de-
tected when a large part of the intracellular domain of the
EGFR was replaced by YFP (HAKED^EGFRv702YFP, Fig.
2B). Dimers were also detected when a large part of the ecto-
domain of RPTPK was further deleted (HAKvED^EGFR-
v702YFP), suggesting that the transmembrane domain of
the EGFR mediated dimerization in vivo (Fig. 2B). The
equivalent constructs of RPTPK (HAKEDv200YFP and HAK
vEDv200YFP) also formed dimers (Fig. 2B) [24]. It is di⁄cult
to compare the di¡erences in band intensity for the dimers
since the crosslinking e⁄ciency will depend on the orientation
and accessibility of tertiary amine-containing amino acids.
Furthermore, technical reasons may be responsible for the
di¡erence, since in our hand higher complexes were always
weakly detected, presumably due to poor blotting (data not
shown). A similar approach has been used successfully to
study the role of the di¡erent domains in RPTPK dimerization
[22] and our results are consistent with reports showing that
the transmembrane domain of RPTPK and of EGFR form
stable dimers in vivo [22,24]. In conclusion, our results indi-
cate that the HARPTPK^EGFR chimera formed dimers to
some extent.
Fig. 1. Model of dimerization-induced transphosphorylation of the
EGFR and chimeric constructs. A: Model for dimerization of the
EGFR by EGF (left) and model of 12CA5-induced dimerization of
the HARPTPK^EGFR chimera (right). KD: kinase domain. B: De-
letion constructs used for the crosslinking experiments (see Section
2).
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3.2. Activation of HARPTPK^EGFR chimeras by 12CA5 is
dependent on the bivalence of the antibody
We investigated if HARPTPK^EGFR was activated by li-
gands. We postulated that the HA-tag in the ectodomain of
RPTPK could be used to induce dimers by addition of biva-
lent 12CA5 anti-HA-tag antibody, thus simulating a potential
ligand by forming a bridge between two chimeras (Fig. 1A).
Indeed, 12CA5 antibody induced activation of the
HARPTPK^EGFR chimeras as detected by tyrosine-phos-
phorylation of the receptor (Fig. 3A). The same e¡ect was
found in transiently transfected 293 cells as in stable NIH-
3T3 cell lines, expressing di¡erent levels of fusion proteins,
although basal levels of tyrosine phosphorylation varied
from experiment to experiment (data not shown). The e¡ect
was speci¢c since the same 12CA5 antibody had no e¡ect on
EGFR (Fig. 3B) and untagged chimera (RPTPK/EGFR, Fig.
5C and data not shown) and was sustained for at least 1 h
(Fig. 3C). Furthermore, addition of the 12CA5 antibody led
to MAPK activation (Fig. 3C), indicating functional activa-
tion of HARPTPK^EGFR. In conclusion, we show that
HARPTPK^EGFR can be activated by an antibody recogniz-
ing the HA-tag in the ectodomain of the fusion protein.
We further investigated if the activation was due to dimer-
ization or to aggregation. We made use of Fab fragments
from the 12CA5 antibody. Fab fragments are monovalent,
but are still able to bind to the HA epitope, although may
be less e⁄ciently. 12CA5-Fab fragments by themselves did not
induce HARPTPK^EGFR tyrosine phosphorylation (Fig.
4A). However, preincubation of stably expressing
HARPTPK^EGFR cells with 12CA5-Fab fragments reduced
the 12CA5-induced activation in a concentration dependent
manner (Fig. 4A). This indicates that the 12CA5-Fab frag-
ments are able to compete with the antibody by binding to
the HA-tag of the HARPTPK^EGFR chimeras. Furthermore,
although 12CA5-Fab fragments were unable to induce activa-
tion, preincubation of the Fab fragments with GAM antibody
(restoring bivalence) induced activation of HARPTPK^EGFR
(Fig. 4B). Other agents inducing aggregation of glycoproteins
like concanavalin A or wheat germ agglutinin had no e¡ect on
the tyrosine phosphorylation of HARPTPK^EGFR (Fig. 4C
and data not shown). Nevertheless, concanavalin A still in-
duced MAPK activation (Fig. 4C), presumably by activating
receptors other than HARPTPK^EGFR, by aggregation. Our
results clearly indicate that activation of HARPTPK^EGFR
by 12CA5 is dependent on the bivalence of the antibody,
suggesting that HARPTPK^EGFR is regulated by dimeriza-
tion. The bivalent antibody may not induce dimerization de
novo, but instead may induce a change in the relative orien-
tation of the two monomers in preformed dimers. In general,
the orientation of two receptors relative to each other within
the dimer may a¡ect receptor activity [25]. The best-charac-
terized example is the erythropoietin receptor (EpoR) for
which a speci¢c orientation between the two monomers, driv-
en by ligand binding, is required for full activation of down-
stream events [26]. The same may be applicable to the EGFR
and may explain the existence of low and high a⁄nity recep-
tors [27,28]. Furthermore, in the context of RPTPK, confor-
mational changes in preformed dimers may be favored in
response to ligands because of the intrinsic potential of RPTPK
to dimerize in vivo (Fig. 2B) [22].
The use of antibody to induce dimerization and activation
is not new for RPTKs. Many examples exist that used speci¢c
antibodies for the ectodomain of the RPTK in question, for
instance the EGFR and the EpoR [26,27]. We developed a
system that applies the widely used HA-epitope-tag and
12CA5, the speci¢c monoclonal antibody that recognizes the
HA-tag. Such a system has a few advantages. First, it does
not require the production of receptor speci¢c antibodies
[26,27]. Second, it allows speci¢c dimerization of the HA-
tagged receptor in the presence or absence of endogenous
receptor. Finally, it is presumably completely cell type inde-
pendent. Taken together, the system should allow the study of
Fig. 2. Constitutive HARPTPK^EGFR dimers. A: 293 cells were transiently transfected with HARPTPK^EGFR, and crosslinked with BS3 (+)
(see Section 2) or left in PBS (3). Equal amounts of proteins were resolved on SDS^PAGE and probed with 12CA5 antibody. B: 293 cells
transiently transfected with the indicated constructs with the ectodomain of RPTPK (KED) or without (KvED) were crosslinked using BS3 (+)
or not (3). Equal amounts of proteins were resolved on SDS^PAGE and probed with 12CA5 antibody. The monomers are indicated on the
right as ‘m’ and ‘M’ with the corresponding dimers indicated as ‘d’ and ‘D’ respectively. Molecular weight markers are indicated on the left.
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any receptor in any cell type. Limitations are that the epitope
tag may by itself induce conformational changes in the ecto-
domain, and may not be optimal for antibody induced dimer-
ization. However, we did not encounter problems with RPTPK
in these respects, but in general, this approach may require
receptor speci¢c optimization.
Although 12CA5 binding to HARPTPK^EGFR brought
the two kinase domains to close proximity allowing activa-
tion, we do not know what the intracellular e¡ect on
HARPTPK would be. Addition of the antibody may bring
close or pull apart the intracellular PTP domain. Further-
more, it is not known if antibody binding would be su⁄cient
to disrupt or change the con¢guration of the transmembrane
dimer and/or the D1^D1 dimer [20,22]. However, the fact that
dimerization of RPTPK ectodomain can be modulated by li-
gand binding provides the ¢rst evidence that ligand(s) may
a¡ect RPTPK.
Fig. 3. Activation of the HARPTPK^EGFR chimeras by addition
of 12CA5 antibody. A: NIH3T3 cells stably expressing HARPTPK^
EGFR were serum-starved and stimulated with 12CA5 antibodies
(V1 Wg/ml) for 15 or 30 min as indicated. HARPTPK^EGFR was
immunoprecipitated using 12CA5 antibody, and probed with PY20
antibody (top panel). After stripping, the same immunoblot was re-
probed with 12CA5 antibody (bottom panel). B: NIH3T3 cells sta-
bly overexpressing EGFR were stimulated with nothing (3), 12CA5
or EGF (50 ng/ml) for 15 min. EGFR was immunoprecipitated
with anti-EGFR antibody and analyzed for their phosphotyrosine
content with PY20 (top panel). After stripping the same immuno-
blot was reprobed with anti-EGFR antibody (bottom panel). C:
NIH3T3 cells stably expressing HARPTPK^EGFR were stimulated
with 12CA5 for the indicated time. HARPTPK^EGFR was immu-
noprecipitated with 12CA5 antibody, and probed with PY20 anti-
body (top panel). Aliquots of the whole cell lysate was probed with
anti-Mapk (bottom). Proteins of interest are indicated with an ar-
row. pMapk is phosphorylated, activated Mapk.
Fig. 4. HARPTPK^EGFR activation is dependent on the bivalence
of the antibody. A: NIH3T3 cells stably expressing HARPTPK^
EGFR were serum-starved and preincubated as indicated with noth-
ing (3) or with 12CA5-Fab fragments for 15 min (1U, V0.5 Wg/ml
and 10U, V5 Wg/ml) before addition of 12CA5 antibody (V1 Wg/
ml) for another 30 min (HA) or not (3). After anti EGFR immu-
noprecipitation, the phosphotyrosine content of HARPTPK^EGFR
was tested with PY20 (top panel). The same blot was reprobed with
anti-EGFR antibody (bottom panel). B: NIH3T3 cells stably ex-
pressing HARPTPK^EGFR were serum-starved and incubated with
12CA5 antibody (12CA5), 12CA5-Fab fragments (Fab), GAM anti-
body or a mixture of pre-coupled 12CA5-Fab fragments and GAM
antibody for 30 min. After anti-EGFR immunoprecipitation, the
phosphotyrosine content of HARPTPK^EGFR was tested with
PY20 (top panel). The same blot was reprobed with anti EGFR
antibody (bottom panel). C: NIH3T3 cells stably expressing
HARPTPK^EGFR were serum-starved and stimulated with 12CA5
antibodies (HA) or with Concanavalin A (50 Wg/ml) for 15 min.
After 12CA5 immunoprecipitation, the phosphotyrosine content was
tested with PY20 (top panel), and whole cell lysate was probed with
anti-Mapk (bottom panel).
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3.3. NCS may contain a ligand for RPTPK
The identi¢cation of ligand is crucial to understand the
function of a receptor. However, ligand identi¢cation can be
time consuming and fastidious. Having shown that the dimer-
ization state of the HARPTPK^EGFR could be altered and
detected by tyrosine phosphorylation, we used the chimeric
construct to test potential ligand for the ectodomain of
RPTPK. In a broad attempt to test for ligand(s) of RPTPK,
we tested sera, NCS and FCS. Interestingly, e¡ects were de-
tected when NCS was added to the medium. Stimulation of
growing cells with NCS led to a small but reproducible de-
crease in basal level tyrosine phosphorylation of RPTPK^
EGFR, but not EGFR (Fig. 5A). Although the NCS-induced
decrease in RPTPK^EGFR tyrosine phosphorylation is repro-
ducible, the extent of the decrease is variable (cf. Fig. 5A,B),
which is presumably due to the di¡erences in experimental
conditions. The same e¡ects were detected in serum-starved
cells, although the lower basal tyrosine phosphorylation of the
receptor made the e¡ect of NCS di⁄cult to observe (data not
shown). In addition, NCS had a negative e¡ect on the 12CA5-
induced activation of HARPTPK^EGFR (Fig. 5B), suggesting
possible competition between the ligand in NCS and the anti-
body. The e¡ect of NCS was speci¢c for the ectodomain of
RPTPK since NCS did not a¡ect tyrosine phosphorylation of
the EGFR in the absence (Fig. 5A) or in the presence of EGF
(Fig. 5B) excluding an indirect e¡ect of NCS on the receptor
(activation of phosphatases, for example). Interestingly, stim-
ulation with FCS had no e¡ect on tyrosine phosphorylation
of HARPTPK^EGFR or RPTPK^EGFR (Fig. 5C, data not
shown). These results suggest that (a) component(s) in NCS
(but not in FCS) are able to a¡ect the dimerization state of
RPTPK^EGFR through binding to the ectodomain of RPTPK,
further suggesting that potential ligands for RPTPK are
present in NCS. We do not know if ligand binding induced
either monomerization of HARPTPK^EGFR or stabilization
of an inactive dimeric state. Since RPTPK’s activity may be
regulated by dimerization [20], it is tempting to speculate that
RPTPK activity may be regulated by external stimuli that
a¡ect its dimerization state and thus activity. Analysis of
the e¡ect of NCS on RPTPK activity is hampered by the
fact that NCS contains too many factors that have too
many direct and indirect e¡ects on the cell (for example,
Src, a known substrate of RPTPK may be regulated independ-
ently of RPTPK by speci¢c NCS components [29]). Further
puri¢cation and identi¢cation of the ligand will be required to
test the direct e¡ect of this ligand on RPTPK activity.
Little is known about the regulation of RPTP activity by
ligand-induced dimerization. Here, we describe a system that
may be used to characterize ligand(s) and/or to study RPTP
signaling by 12CA5-induced dimerization. Moreover, it will
be interesting to use similar systems to test the e¡ect of po-
tential ligands on dimerization and activity of other RPTPs,
e.g. the e¡ect of pleiotrophin on RPTPL dimerization and
activation. Recently, Contactin, a GPI-anchored protein was
suggested to act as a ligand for RPTPK [15]. Contactin was
shown to bind to RPTPK in cis, excluding Contactin as being
the ligand in the NCS. It will be interesting to see the e¡ect of
Contactin on HARPTPK^EGFR dimerization.
In conclusion, using an antibody dependent dimerization
system, we show that the ectodomain of RPTPK can mediate
ligand binding, leading to intracellular signaling. Further-
more, we show that NCS contains endogenous ligand(s) for
RPTPK, suggesting that RPTPK dimerization and thus activ-
ity may be regulated by extracellular signals.
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